RenuvoGen
Exclusive U.S. Distributor of the GCell Medical Device — Pioneering point-of-care autologous stem cell isolation machine for regenerative medicine, aesthetic therapy, and hair restoration.



Our Mission
Regenerative Medicine, Redefined at the Point of Care
RenuvoGen is dedicated to bringing the most advanced, clinically validated autologous cell therapy solutions to medical professionals, clinic owners, and regenerative medicine specialists across the United States.
As the exclusive distributor of the GCell Medical Device, we empower providers to isolate and deploy a patient's own stem cells — safely, efficiently, and in full regulatory compliance — without the need for a central processing laboratory.
Why RenuvoGen?
  • Exclusive U.S. distribution rights for the GCell platform
  • End-to-end clinical support and training
  • FDA/CE-registered device compliance
  • Proven outcomes in orthopedics, aesthetics, and hair restoration
  • Rapid, same-session cell deployment for patients
The Device
Introducing the GCell Autologous Tissue Separation Device
The GCell is a CE-marked, closed-system medical device engineered for same-session autologous tissue processing. Designed for clinic use, it isolates viable mesenchymal stem cells (MSCs), stromal vascular fraction (SVF), and hair follicle progenitor cells from a patient's own adipose or follicular tissue — all within a single, streamlined procedure.
GCell Technology
How the GCell Works
The GCell's closed-loop architecture eliminates contamination risk while enabling a fully autologous workflow — from tissue harvest to cell reinjection — in under 90 minutes. No external lab. No cryopreservation delays. No batch processing. Just viable, patient-matched cells ready for immediate therapeutic use at the point of care.
Cell Type 1
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells are adult, multipotent stem cells capable of self-renewal and differentiation into multiple cell lineages — including adipocytes, osteoblasts, chondrocytes, and myocytes. The GCell isolates MSCs directly from a patient's own adipose (fat) tissue harvested via minimally invasive mini-lipoaspiration.
Clinical Properties
  • Potent immunomodulatory and anti-inflammatory signaling
  • Paracrine secretion of growth factors and cytokines
  • Capacity for tissue repair and regeneration
  • High viability when autologously sourced and same-session deployed
  • No risk of immune rejection — 100% patient-matched
Cell Type 2
Stromal Vascular Fraction (SVF)
SVF is a heterogeneous, biologically rich mixture of cells derived from adipose tissue — including MSCs, endothelial progenitor cells, pericytes, macrophages, and regulatory T-cells. Together, this cellular consortium frequently demonstrates stronger anti-inflammatory and angiogenic effects than purified MSCs alone, making SVF a highly versatile therapeutic agent.
Anti-Inflammatory
Multi-cellular signaling suppresses chronic inflammation more effectively than single-cell preparations.
Angiogenic
Endothelial progenitors and pericytes stimulate new blood vessel formation, supporting tissue perfusion and healing.
Regenerative
The full SVF matrix delivers growth factors, ECM remodeling signals, and paracrine support for comprehensive tissue repair.
Cell Type 3
Hair Follicle Progenitor Cells for Hair Restoration
Unipotent Progenitors
Slow-cycling, lineage-restricted stem cells found in the hair bulge and germ. They activate during the anagen (growth) phase to regenerate the follicle.
Keratinocytes
Primary structural cells of the hair shaft. Keratinocyte stem cells in the follicle bulge drive shaft elongation and cortex formation during active growth cycles.
Melanocyte Stem Cells
Pigment-producing progenitors that regenerate melanocytes with each hair cycle, restoring color and supporting follicle vitality.
By isolating these specialized follicular progenitors, the GCell enables clinicians to enhance hair transplant outcomes, promote de novo hair growth, and support healing and engraftment in transplant patients — all using cells derived from the patient's own scalp or follicular tissue.
Clinical Applications
A Platform for Multiple Regenerative Specialties
Orthopedics & Sports Medicine
MSC and SVF injections for osteoarthritis, tendon injuries, ligament repair, and post-surgical recovery. Reduce inflammation and stimulate cartilage regeneration with autologous cells.
Aesthetic & Anti-Aging Medicine
Harness MSC-derived growth factors for skin rejuvenation, volumization, and wound healing. SVF provides a potent, natural alternative to synthetic fillers and growth factor serums.
Hair Restoration & Transplantation
Follicular progenitor cells and MSCs enhance hair transplant survival rates, stimulate dormant follicles, and promote scalp healing — supporting both surgical and non-surgical hair restoration protocols.
Regulatory & Safety Profile
Designed for Compliance. Built for Clinical Confidence.
Regulatory Status
The GCell is a CE-marked medical device manufactured in compliance with international standards for autologous cell processing. RenuvoGen supports U.S.-based clinics in navigating FDA guidelines for point-of-care, same-surgical-procedure autologous cell therapy.
As a closed, non-expanded, same-session system, the GCell is designed to align with FDA's minimal manipulation, homologous use framework under 21 CFR Part 1271.
Key Safety & Compliance Advantages
Closed System
No open processing — eliminates environmental contamination risk throughout the entire cell isolation workflow.
Autologous Only
100% patient-matched cells — zero risk of immune rejection, disease transmission, or donor-matching complications.
No Cell Expansion
Cells are isolated and reinjected in the same session without in vitro expansion, maintaining the minimal manipulation standard.
Why Choose RenuvoGen
The Competitive Advantage of GCell at Your Clinic
Same-Session Treatment
Harvest, process, and reinject — all within a single patient visit. No lab wait times. No frozen samples. Maximize clinical efficiency and patient experience.
CE-Registered Device
Deploy with confidence. The GCell carries full CE certification with documentation support for clinical compliance across all specialties.
Triple Cell Output
One device. Three cell types — MSCs, SVF, and hair follicle progenitors — unlocking multiple revenue streams and treatment protocols from a single platform.
Full Clinical Support
RenuvoGen provides comprehensive onboarding, protocol training, marketing materials, and ongoing clinical consultation for every practice partner.
For Clinic Owners & Investors
A High-Value Addition to Any Regenerative Practice
Revenue Opportunity
  • Expand service offerings across orthopedics, aesthetics, and hair restoration
  • Command premium pricing for autologous, same-session regenerative protocols
  • Differentiate your clinic with exclusive, CE-certified technology
  • Low per-procedure consumable cost relative to treatment fees
Operational Simplicity
  • Compact, tabletop device — no dedicated lab space required
  • Minimal staff training with RenuvoGen's structured onboarding program
  • Standardized protocol kits for consistent, reproducible results
  • Dedicated account management and reorder support from RenuvoGen
Get Started
Partner with RenuvoGen
RenuvoGen is actively onboarding clinic partners, regenerative medicine specialists, and investment partners across the United States. As the exclusive U.S. distributor of the GCell Medical Device, we offer a structured partnership model with full commercial and clinical support.
01
Request a Consultation
Speak with a RenuvoGen clinical specialist to assess your practice needs and treatment goals.
02
Device Demo & Protocol Review
Receive a live GCell demonstration and review clinical protocols tailored to your specialty.
03
Onboard & Launch
Complete training, receive your device and starter kits, and begin offering autologous cell therapy to your patients.


Contact RenuvoGen
Website: renuvogen.com
Phone: 800-940-3060


Whether you are a physician, clinic owner, or investor evaluating the regenerative medicine market, RenuvoGen is your trusted partner for point-of-care stem cell isolation technology.